Physician profile
Matthew Davis
NPI 1548420193
$1,961.76
in general payments reported to CMS, 2019-2025
15 companies · $444 in 2025
The $444 reported for 2025 was more than what 92% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.89 · 2020: $14.35 · 2021: $73.05 · 2022: $194 · 2023: $501 · 2024: $698 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,642.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $859.73 | 2022-2024 | Inspire |
| Boston Scientific Corporation | $569.67 | 2023-2025 | Ams 700, General - Erectile Dysfunction |
| Progenics Pharmaceuticals, INC. | $124.98 | 2025 | |
| Bioxcel Therapeutics, INC. | $115.26 | 2024 | Igalmi |
| Ethicon US, LLC | $52.98 | 2021-2022 | |
| Gilead Sciences, INC. | $48.12 | 2021 | |
| Neurocrine Biosciences, INC. | $35.05 | 2025 | |
| Harmony Biosciences LLC | $31.15 | 2025 | |
| Zyla Life Sciences, INC. | $23.85 | 2019 | |
| Merz Pharmaceuticals, LLC | $18.76 | 2025 | Inbrija |
| Astrazeneca Pharmaceuticals Lp | $18.27 | 2024 | Andexxa |
| Chiesi USA, INC. | $18.23 | 2025 | Cleviprex |
| Octapharma USA, INC. | $17.32 | 2024 | Balfaxar |
| Janssen Pharmaceuticals, INC | $14.35 | 2020 | |
| Lilly USA, LLC | $14.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.